Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Advances in antibody–drug conjugates: A new era of targeted cancer therapy

Open access
Sau, Samaresh, Alsaab, Hashem O., Kashaw, Sushil Kumar, Tatiparti, Katyayani, Iyer, Arun K.·2017·Drug Discovery Today

Abstract

Antibody–drug conjugates (ADCs), a potent class of anticancer therapeutics, comprise a high-affinity antibody (Ab) and cytotoxic payload coupled via a suitable linker for selective tumor cell killing. In the initial phase of their development, two ADCs, Mylotarg®, and Adcetris® were approved by the US Food and Drug Administration (FDA) for treating hematological cancer, but the real breakthrough came with the discovery of the breast cancer-targeting ADC, Kadcyla®. With advances in bioengineering, linker chemistry, and potent cytotoxic payload, ADC technology has become a more powerful tool for targeted cancer therapy. In addition, ADCs with improved safety using humanized Abs with a unified ‘drug:antibody ratio’ (DAR) have been achieved. Concomitantly, there has been a significant increase in the number of clinical trials with anticancer ADCs with high translation potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2017.05.011

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 174

Metadata

Authors
Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K., & Iyer, A. K.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2017-10
Volume
22
Issue
10
Pages
1547-1556
ISSN
1359-6446 (ISSN-L)
OpenAlex
W2626436697
Cited by
174
References
4
FWCI
17.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in antibody–drug conjugates: A new era of targeted cancer therapy. https://app.cochat.ai/papers/10.1016/j.drudis.2017.05.011
The paper
Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K., & Iyer, A. K. (2017). Advances in antibody–drug conjugates: A new era of targeted cancer therapy. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2017.05.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.